Payload Information

General Information of This Payload

Payload ID	PAY0HRHLR
Name	Deglycosylated ricin A-chain (dgA)
Synonyms	Deglycosylated ricin A-chain (dgA) Click to Show/Hide
Target(s)	.	Target Info

The activity data of This Payload

Standard Type	Value	Units	Cell line	Disease Model	Cell line ID	Reference
Half Maximal Inhibitory Concentration (IC50)	124	ug/mL	Daudi cells	Burkitt lymphoma	CVCL_0008	[1]

Each Antibody-drug Conjugate Related to This Payload

Full Information of The Activity Data of The ADC(s) Related to This Payload

Anti-gp41 mAb ricin A chain [Investigative]

ADC Info

Revealed Based on the Cell Line Data

Click To Hide/Show 2 Activity Data Related to This Level

Experiment 1 Reporting the Activity Date of This ADC				[2]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.20 ng/mL -125 ng/mL
Method Description	Target cells (1000-2000) were plated in triplicate in 96-well flat bottom tissue culture plates in 100 uL tissue culture medium in the presence of the indicated concentration of mAb for 1 h at 37. The secondary immunotoxin, goat anti-human IgG conjugated to ricin A chain, was then added at a final concentration of 300 ng/mL in 100 uL, and the cells were incubated for 3 days. Click to Show/Hide
In Vitro Model	Human immunodeficiency virus type 1	HEK293/92UG cells	.
Experiment 2 Reporting the Activity Date of This ADC				[2]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	8 ng/mL - 15 ng/mL
Method Description	Target cells (1000-2000) were plated in triplicate in 96-well flat bottom tissue culture plates in 100 uL tissue culture medium in the presence of the indicated concentration of mAb for 1 h at 37. The secondary immunotoxin, goat anti-human IgG conjugated to ricin A chain, was then added at a final concentration of 300 ng/mL in 100 uL, and the cells were incubated for 3 days. Click to Show/Hide
In Vitro Model	Human immunodeficiency virus type 1	H9/NL4-3 cells	.

References

Ref 1	Laboratory preparation of a deglycosylated ricin toxin A chain containing immunotoxin directed against a CD7 T lineage differentiation antigen for phase I human clinical studies involving T cell malignancies. J Immunol Methods. 1996 Oct 16;197(1-2):69-83.
Ref 2	Identification of Anti-gp41 Monoclonal Antibodies That Effectively Target Cytotoxic Immunoconjugates to Cells Infected with Human Immunodeficiency Virus, Type 1. Vaccines (Basel). 2023 Apr 12;11(4):829. doi: 10.3390/vaccines11040829.